Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Ha, Yun Sok ^a   Lee, Geun T ^b   Kim, Ye Hwan ^c   Kwon, Se Y ^a   Choi, Seock H ^a   Kim, Tae Hwan ^a   Kwon, Tae G ^a   Yun, Seok J ^c   Kim, Isaac Y ^b   Kim, Wun Jae ^c  

^a Kyungpook National University School of Medicine   (South Korea)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c Chungbuk National University College of Medicine   (South Korea)

Author keywords

Prognostic marker; Renal cell carcinoma; SELEMBP1

Indexed keywords

SELENIUM BINDING PROTEIN; SELENIUM BINDING PROTEIN 1; UNCLASSIFIED DRUG; MESSENGER RNA; SELENBP1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; GENETICS; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SELENIUM-BINDING PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84908147737     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-288     Document Type: Article

References (34)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29. 10.3322/caac.21208, 24399786.
2. Mazzucchelli R, Galosi AB, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. Contemporary update on pathology-related issues of adult renal neoplasms. Anal Quant Cytopathol Histpathol 2014, 36:1-8.
3. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001, 166:1611-1623. 10.1016/S0022-5347(05)65640-6, 11586189.
4. Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, Deshpande A, Menon M. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002, 26:281-291. 10.1097/00000478-200203000-00001, 11859199.
5. Shamberger RJ, Frost DV. Possible protective effect of selenium against human cancer. Can Med Assoc J 1969, 100:682.
6. Virtamo J, Valkeila E, Alfthan G, Punsar S, Huttunen JK, Karvonen MJ. Serum selenium and risk of cancer: a prospective follow-up of nine years. Cancer 1987, 60:145-148. 10.1002/1097-0142(19870715)60:2<145::AID-CNCR2820600203>3.0.CO;2-U, 3594351.
7. Chang PW, Tsui SK, Liew C, Lee CC, Waye MM, Fung KP. Isolation, characterization, and chromosomal mapping of a novel cDNA clone encoding human selenium binding protein. J Cell Biochem 1997, 64:217-224. 10.1002/(SICI)1097-4644(199702)64:2<217::AID-JCB5>3.0.CO;2-#, 9027582.
8. Lanfear J, Fleming J, Walker M, Harrison P. Different patterns of regulation of the genes encoding the closely related 56 kDa selenium- and acetaminophen-binding proteins in normal tissues and during carcinogenesis. Carcinogenesis 1993, 14:335-340. 10.1093/carcin/14.3.335, 8453708.
9. Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, Misek DE, Giordano TJ, Orringer MB, Hanash SM, Beer DG. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol 2004, 202:321-329. 10.1002/path.1524, 14991897.
10. Li T, Yang W, Li M, Byun DS, Tong C, Nasser S, Zhuang M, Arango D, Mariadason JM, Augenlicht LH. Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res 2008, 52:1289-1299. 10.1002/mnfr.200700331, 18435490.
11. Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, Bandera CA, Welch WR, Berkowitz RS, Mok SC, Ng SW. Selenium binding protein 1 in ovarian cancer. Int J Cancer 2006, 118:2433-2440. 10.1002/ijc.21671, 16380993.
12. Yang M, Sytkowski AJ. Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res 1998, 58:3150-3153.
13. Li LS, Kim H, Rhee H, Kim SH, Shin DH, Chung KY, Park KS, Paik YK, Chang J. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics 2004, 4:3394-3400. 10.1002/pmic.200400901, 15378762.
14. Kim H, Kang HJ, You KT, Kim SH, Lee KY, Kim TI, Kim C, Song SY, Kim HJ, Lee C. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 2006, 6:3466-3476. 10.1002/pmic.200500629, 16645984.
15. Zhang J, Dong WG, Lin J. Reduced selenium-binding protein 1 is associated with poor survival rate in gastric carcinoma. Med Oncol 2011, 28:481-487. 10.1007/s12032-010-9482-7, 20354826.
16. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002, 87:13-15.
17. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6:655-663. 10.1097/00000478-198210000-00007, 7180965.
18. Bland JM, Altman DG. Transformations, means, and confidence intervals. BMJ 1996, 312:1079. 10.1136/bmj.312.7038.1079, 2350916, 8616417.
19. Lucas B, Grigo K, Erdmann S, Lausen J, Klein-Hitpass L, Ryffel GU. HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma. Oncogene 2005, 24:6418-6431.
20. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA, Belldegrun AS. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004, 171:2461-2466. 10.1097/01.ju.0000116444.08690.e2, 15126876.
21. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007, 13:7388-7393. 10.1158/1078-0432.CCR-07-0411, 18094421.
22. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000, 163:343-347. 10.1016/S0022-5347(05)68049-4, 10604387.
23. Johnson TV, Abbasi A, Owen-Smith A, Young A, Ogan K, Pattaras J, Nieh P, Marshall FF, Master VA. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. J Urol 2010, 183:480-485. 10.1016/j.juro.2009.10.014, 20006861.
24. de Martino M, Klatte T, Seemann C, Waldert M, Haitel A, Schatzl G, Remzi M, Weibl P. Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC). BJU Int 2013, 111:E348-E353. 10.1111/bju.12067, 23495750.
25. Lucarelli G, Ditonno P, Bettocchi C, Vavallo A, Rutigliano M, Galleggiante V, Larocca AM, Castellano G, Gesualdo L, Grandaliano G, Selvaggi FP, Battaglia M. Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma. Dis Markers 2014, 2014:689795. 3947895, 24692843.
26. Behne D, Kyriakopoulos A. Mammalian selenium-containing proteins. Annu Rev Nutr 2001, 21:453-473. 10.1146/annurev.nutr.21.1.453, 11375445.
27. Jeong JY, Wang Y, Sytkowski AJ. Human selenium binding protein-1 (hSP56) interacts with VDU1 in a selenium-dependent manner. Biochem Biophys Res Commun 2009, 379:583-588. 10.1016/j.bbrc.2008.12.110, 19118533.
28. Porat A, Sagiv Y, Elazar Z. A 56-kDa selenium-binding protein participates in intra-Golgi protein transport. J Biol Chem 2000, 275:14457-14465. 10.1074/jbc.275.19.14457, 10799528.
29. Klein EA. Selenium and vitamin E cancer prevention trial. Ann N Y Acad Sci 2004, 1031:234-241. 10.1196/annals.1331.023, 15753149.
30. Zhang S, Li F, Younes M, Liu H, Chen C, Yao Q. Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium. PLoS One 2013, 8:e63702. 10.1371/journal.pone.0063702, 3660592, 23704933.
31. Zeng GQ, Yi H, Zhang PF, Li XH, Hu R, Li MY, Li C, Qu JQ, Deng X, Xiao ZQ. The function and significance of SELENBP1 downregulation in human bronchial epithelial carcinogenic process. PLoS One 2013, 8:e71865. 10.1371/journal.pone.0071865, 3747066, 23977169.
32. Jerome-Morais A, Wright ME, Liu R, Yang W, Jackson MI, Combs GF, Diamond AM. Inverse association between glutathione peroxidase activity and both selenium-binding protein 1 levels and Gleason score in human prostate tissue. Prostate 2012, 72:1006-1012. 10.1002/pros.21506, 3288333, 22072582.
33. Zhang P, Zhang C, Wang X, Liu F, Sung CJ, Quddus MR, Lawrence WD. The expression of selenium-binding protein 1 is decreased in uterine leiomyoma. Diagn Pathol 2010, 5:80. 10.1186/1746-1596-5-80, 3014888, 21143902.
34. Zhang J, Zhan N, Dong WG. Altered expression of selenium-binding protein 1 in gastric carcinoma and precursor lesions. Med Oncol 2011, 28:951-957. 10.1007/s12032-010-9564-6, 20480265.